Lookup NU author(s): Dr Kaushik Agarwal
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Drotrecogin alfa has been shown to reduce mortality in severe sepsis. However, it remains unlicensed for use in patients with previous liver transplantation. We report its use in such a case. Prior to administration a risk benefit analysis was performed in line with General Medical Council recommendations. This included being satisfied that no appropriately licensed alternative would better serve the patient's needs and that sufficient evidence existed to demonstrate the safety and efficacy of the drug. Responsibility was taken for prescription, monitoring and follow up. The process was carefully documented and the patient recovered fully with no adverse effects. To date the only published data on the use of drotrecogin alpha in transplant recipients is a case series of three patients. Further published data may encourage review of the licence.
Author(s): Browne E, Cressey DM, Agarwal K, Cosgrove JF
Publication type: Article
Publication status: Published
ISSN (print): 0003-2409
ISSN (electronic): 1365-2044
Altmetrics provided by Altmetric